Search results for "EGF"

Expression of angiogenic regulators. VEGF and leptin, is regulated by the EGF/P13K/STAT3 pathway in colorectal cancer cells

2009

Ocular Drug Delivery Systems per la veicolazione di molecole bioattive al segmento posteriore dell'occhio

Kracauer, Siegfried: Werke. Hrsg. von Inka Mülder-Bach und Ingrid Belke. – Frankfurt am Main: Suhrkamp. [Bd.] 4. Geschichte – Vor den letzten Dingen.…

2010

Recensione

TGF-β/VEGF-A Genetic Variants Interplay in Genetic Susceptibility to Non-Melanocytic Skin Cancer

2022

Differential genetically determined expression of transforming growth factor-β (TGF-β pathway and of vascular endothelial growth factor-A (VEGF-A) might modulate the molecular “milieu” involved in the etio-pathogenesis of non-melanoma skin cancer (NMSC). We have evaluated the frequency of some functionally relevant SNPs of TGF-β and VEGF-A genes in 70 NMSC patients and 161 healthy controls, typed for TGF-β1 rs1800471, TGF-β2 rs900, TGF-βR1 rs334348 and rs334349, TGF-βR2 rs4522809 and VEGF-A rs3025039 SNPs. TGF-βR2 rs1800629G allele and related genotypes were found to be associated with a possible protective role against NMSC, whereas VEGF-…

RECHALLENGE WITH ANTI-EGFR MONOCLONAL ANTIBODIES IN PRETREATED METASTATIC COLORECTAL CANCER PATIENTS: BEYOND THE LIMITS OF ACQUIRED RESISTANCE

2012

Background: Scientific data provide today the evidence that secondary K-RAS mutations do not occur during anti-EGFR therapy in CRC patients. This multicenter phase II prospective study aims to investigate the activity of a retreatment with a cetuximab-based therapy. Patients and Methods: we enrolled 39 irinotecan refractory patients who had a clinical benefit after a line of Cetuximab plus irinotecan-based therapy and then a progression of disease for which underwent a new line chemotherapy and finally, after a clear new progression of disease, were re-treated with the same Cetuximab plus Irinotecan based therapy. Results: Median number of therapeutic lines before accrual was 4. Median inte…

Hepatocellular carcinoma treatment over sorafenib: epigenetics, microRNAs and microenvironment. Is there a light at the end of the tunnel?

2015

Introduction: Sorafenib is currently the only approved therapy in hepatocellular carcinoma (HCC). Alternative first- and second-line treatments are a significant unmet medical need, and several biologic agents have been tested in recent years, with poor results. Therefore, angiogenic pathways and the cytokine cascade remain possible targets in HCC. Recent studies suggest a role of epigenetic processes, associated with the initiation and development of HCC. In this field, DNA methylation, micro-RNAs (miRNAs) and tumor microenvironment cells became a possible new target for HCC treatment. Areas covered: This review explains the possible role of DNA methylation and histone deacetylase inhibito…

The role of microRNAs in driving EGFR-TKI resistance in NSCLC cell lines

2016

Background: the inhibition of EGFR kinase activity by tyrosine kinase inhibitors (EGFR-TKIs), such as gefitinib and erlotinib, can result in improved response and prolonged progression-free survival (PFS) in NSCLC patients harboring sensitizing exon 19del and exon 21 L858R mutations. Unfortunately, almost all patients will develop resistance to EGFR-TKI, in particular T790M is the most frequent mutation. Nowadays, new methods are urgently needed for a rapid, cost-effective and non-invasive identification of biomarkers as a valuable tool for obtaining the genetic follow-up data during the course of the disease. Circulating microRNAs might represent a new precious biomarker for patients’ moni…

PROGNOSTIC VALUE OF ESTIMATED GLOMERULAR FILTRATION RATE IN HOSPITALIZED ELDERLY PATIENTS

2013

A multicenter observational study, REPOSI (REgustri POliterapie Società Italiana di Medicina Interna), was conducted to assess the prognostic value of glomerular filtration rate (eGFR) on in-hospital mortality, hospital readmission and death within 3 months, in a sample of elderly patients (n=1,363) admitted to 66 internal medicine and geriatric wards. Bases on eGFR, calculated by the new Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula, subjects at hostpital admission were classified into three groups: group 1 with normal eGFR (60 ml/min/1.73m2, reference group), group 2 with moderately reduced eGFR (30-59 ml/min/1.73 m2) and group 3 with severely reduced eGFR (<30 ml/m…

Adipose tissue in sleep apnea: effects of hypoxia and inflammation

2014

Is Ranibizumab effective in stopping loss of vision secondary to Choroidal Neovascularization in Pathologic Myopia? A Long Term Follow-up Study.

2011

Purpose: To assess the efficacy and safety of Ranibizumab in the treatment of choroidal neovascularization (CNV) caused by pathologic myopia (PM). Design: Prospective, multicenter, interventional case series. Methods: 40 of 39 consecutive patients with PM and CNV were treated with “on-demand” intravitreal injection of ranibizumab 0.5 mg. Final best-corrected VA (BCVA) and its change from baseline were the main outcome measures. Changes in Optical Coherence Tomography (OCT) central retinal thickness (CRT) were a secondary outcome. Results: Mean age was 53 ± 13 years, mean refractive error -13.5 ± 6.5 diopters. Median follow-up was 13.3 ± 2 months (range 12 – 18). Fifteen eyes (37.5%) had pre…